PubMed:33020836
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 224-235 | Body_part | denotes | pneumocytes | http://purl.org/sig/ont/fma/fma62499 |
T2 | 248-256 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
T3 | 719-721 | Body_part | denotes | CS | http://purl.org/sig/ont/fma/fma284995 |
T4 | 777-779 | Body_part | denotes | CS | http://purl.org/sig/ont/fma/fma284995 |
T5 | 1227-1229 | Body_part | denotes | CS | http://purl.org/sig/ont/fma/fma284995 |
T6 | 1233-1235 | Body_part | denotes | CS | http://purl.org/sig/ont/fma/fma284995 |
T7 | 1627-1629 | Body_part | denotes | CS | http://purl.org/sig/ont/fma/fma284995 |
T8 | 1637-1639 | Body_part | denotes | CS | http://purl.org/sig/ont/fma/fma284995 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 87-95 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T2 | 98-107 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T3 | 280-288 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T4 | 291-300 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T5 | 443-451 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T6 | 454-463 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T7 | 541-549 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T8 | 552-561 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T9 | 1698-1706 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T10 | 1709-1718 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 140-150 | http://purl.obolibrary.org/obo/BFO_0000030 | denotes | OBJECTIVES |
T2 | 563-571 | http://purl.obolibrary.org/obo/UBERON_0001637 | denotes | arterial |
T3 | 563-571 | http://www.ebi.ac.uk/efo/EFO_0000814 | denotes | arterial |
T4 | 1134-1135 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T5 | 1291-1293 | http://purl.obolibrary.org/obo/CLO_0050507 | denotes | 22 |
T6 | 1311-1312 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T7 | 1719-1720 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 67-82 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
T2 | 175-184 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T3 | 404-419 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
T4 | 572-578 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T5 | 624-630 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T6 | 662-681 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T7 | 662-671 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T8 | 672-681 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T9 | 702-717 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
T10 | 719-721 | Chemical | denotes | CS | http://purl.obolibrary.org/obo/CHEBI_73462 |
T11 | 722-727 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T12 | 740-755 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
T13 | 777-779 | Chemical | denotes | CS | http://purl.obolibrary.org/obo/CHEBI_73462 |
T14 | 780-785 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T15 | 836-842 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T16 | 1011-1017 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T17 | 1227-1229 | Chemical | denotes | CS | http://purl.obolibrary.org/obo/CHEBI_73462 |
T18 | 1233-1235 | Chemical | denotes | CS | http://purl.obolibrary.org/obo/CHEBI_73462 |
T19 | 1236-1241 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T20 | 1365-1371 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T21 | 1627-1629 | Chemical | denotes | CS | http://purl.obolibrary.org/obo/CHEBI_73462 |
T22 | 1637-1639 | Chemical | denotes | CS | http://purl.obolibrary.org/obo/CHEBI_73462 |
T23 | 1640-1645 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T24 | 1753-1768 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
T25 | 1850-1865 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 98-107 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T2 | 248-262 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
T3 | 291-300 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T4 | 454-463 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T5 | 552-561 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T6 | 1709-1718 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-139 | Sentence | denotes | Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. |
T2 | 140-151 | Sentence | denotes | OBJECTIVES: |
T3 | 152-301 | Sentence | denotes | The Janus kinase (JAK) inhibitor baricitinib may block viral entry into pneumocytes and prevent cytokine storm in patients with SARS-CoV-2 pneumonia. |
T4 | 302-464 | Sentence | denotes | We aimed to assess whether baricitinib improved pulmonary function in patients treated with high-dose corticosteroids for moderate to severe SARS-CoV-2 pneumonia. |
T5 | 465-473 | Sentence | denotes | METHODS: |
T6 | 474-795 | Sentence | denotes | This observational study enrolled patients with moderate to severe SARS-CoV-2 pneumonia [arterial oxygen partial pressure (PaO2)/fraction of inspired oxygen (FiO2) <200 mmHg] who received lopinavir/ritonavir and HCQ plus either corticosteroids (CS group, n = 50) or corticosteroids and baricitinib (BCT-CS group, n = 62). |
T7 | 796-930 | Sentence | denotes | The primary end point was the change in oxygen saturation as measured by pulse oximetry (SpO2)/FiO2 from hospitalization to discharge. |
T8 | 931-1049 | Sentence | denotes | Secondary end points included the proportion of patients requiring supplemental oxygen at discharge and 1 month later. |
T9 | 1050-1124 | Sentence | denotes | Statistics were adjusted by the inverse propensity score weighting (IPSW). |
T10 | 1125-1133 | Sentence | denotes | RESULTS: |
T11 | 1134-1290 | Sentence | denotes | A greater improvement in SpO2/FiO2 from hospitalization to discharge was observed in the BCT-CS vs CS group (mean differences adjusted for IPSW, 49; 95% CI: |
T12 | 1291-1310 | Sentence | denotes | 22, 77; P < 0.001). |
T13 | 1311-1472 | Sentence | denotes | A higher proportion of patients required supplemental oxygen both at discharge (62.0% vs 25.8%; reduction of the risk by 82%, OR adjusted for IPSW, 0.18; 95% CI: |
T14 | 1473-1596 | Sentence | denotes | 0.08, 0.43; P < 0.001) and 1 month later (28.0% vs 12.9%, reduction of the risk by 69%, OR adjusted for IPSW, 0.31; 95% CI: |
T15 | 1597-1646 | Sentence | denotes | 0.11, 0.86; P = 0.024) in the CS vs BCT-CS group. |
T16 | 1647-1661 | Sentence | denotes | CONCLUSIONS: . |
T17 | 1662-1872 | Sentence | denotes | In patients with moderate to severe SARS-CoV-2 pneumonia a combination of baricitinib with corticosteroids was associated with greater improvement in pulmonary function when compared with corticosteroids alone. |
T18 | 1873-1892 | Sentence | denotes | TRIAL REGISTRATION: |
T19 | 1893-2047 | Sentence | denotes | European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, ENCEPP (EUPAS34966, http://www.encepp.eu/encepp/viewResource.htm? id = 34967). |
hydroxychloroquine
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 98-107 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T2 | 248-262 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
T3 | 291-300 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T4 | 454-463 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T5 | 552-561 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T6 | 1709-1718 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |